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Dyspnea and Inhaled Corticosteroid and Long-acting
b-Agonist Therapy in an Occupational Cohort:
A Longitudinal Study
To the Editor:
Inhaled corticosteroids in combination with long-acting b-agonists
(ICS/LABA) are commonly used to treat fixed and variable
obstructive lung diseases (1–6). Current treatment guidelines are
based on clinical trials with restricted data before ICS/LABA
initiation. Research on the trajectories of respiratory symptoms
before and after ICS/LABA initiation is limited. Fire Department of
the City of New York (FDNY) rescue/recovery workers experienced
a massive irritant exposure after the collapse of the World Trade
Center (WTC) on September 11, 2001 (9/11), resulting in increased
rates of respiratory symptoms, as well as an acute drop in lung
function associated with reactive airway disease and fixed airflow
obstruction (7–13). Using longitudinal data on respiratory
symptoms, the aims of the present study were to analyze changes in
dyspnea before and after ICS/LABA initiation and to determine
whether time between WTC exposure and treatment initiation was
associated with treatment response.
Methods
The source population consisted of 9,638 male firefighters who
were employed by FDNY on 9/11, first arrived at the WTC site
between 9/11 and September 24, 2001, and underwent at least three
routine medical monitoring examinations between 9/11 and
September 10, 2018. The study population (N= 1,073; 11% of the
source population) consisted of those who had ICS/LABA
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Figure 1. Forest plot showing variables associated with being included in the study population and receiving inhaled corticosteroid (ICS)/long-acting
b-agonist (LABA) treatment for longer than 2 years versus not receiving ICS/LABA treatment (n=7,777). Results shown are from a multivariable logistic
regression analysis performed to determine the associations between first post-9/11 medical monitoring data and ICS/LABA treatment for longer than 2
years (odds ratios and 95% confidence intervals [bars]); data are also adjusted for race. FEV1 = forced expiratory volume in 1 second; FVC= forced vital
capacity; mMRC=modified Medical Research Council dyspnea scale; WTC=World Trade Center.
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treatment for longer than 2 years after 9/11 and had at least one
modified Medical Research Council (mMRC) dyspnea scale score
(14) before and at least two mMRC scores after ICS/LABA
initiation. The study population completed 7,835 medical
monitoring questionnaires, including mMRC scores, between
August 1, 2005 and September 10, 2018. Written informed consent
was provided by all participants.
Demographics, height, weight, smoking status, initial arrival
time at the WTC site (WTC exposure level), and spirometric
measurements were retrieved from the FDNY employee database
and/or assessed during routine medical monitoring examinations.
Medication data were obtained from the FDNY electronic medical
record and/or pharmacy claims data. Treatment duration was
defined as the interval between first and latest fill dates of
ICS/LABA. Multivariable-adjusted logistic regression determined
variables associated with being in the study population of
ICS/LABA-treated individuals versus not receiving ICS/LABA
treatment (n= 6,721). Individuals classified as “responders” to
ICS/LABA were those who had an mMRC slope less than 0 after
treatment initiation; “nonresponders” had an mMRC slope greater
than or equal to 0. Longitudinal mMRC scores in responders and
nonresponders were estimated using linear mixed effects models
with random intercepts, with categorized year from ICS/LABA
initiation, age, body mass index (BMI), and race as fixed effects.
Multivariable logistic regression assessed pretreatment mMRC and
time from 9/11 to treatment initiation as predictors for treatment
response, adjusting for age and BMI pretreatment, race, ever-
smoking status, and WTC exposure level.
Data analyses were performed using SAS version 9.4 software
(SAS Institute). Figures were created with Prism 8 software
(GraphPad Software).
Results
The study population included 1,073 individuals who received ICS/
LABA therapy for more than 2 years and had at least one mMRC
score before and two mMRC scores after ICS/LABA initiation. The
mean (6 standard deviation) numbers of mMRC scores were
4 (62) before ICS/LABA initiation and 6 (63) after ICS/LABA
initiation. Individuals from the study population had higher WTC
exposure, first post-9/11 mMRC score, blood eosinophils, and BMI
and lower first post-9/11 lung function than those who did not
receive ICS/LABA treatment (Figure 1).
Responders (571 of 1,073; 53%) were more likely to be ever-
smokers (36% vs. 33%) but had pretreatment lung function similar
to that of nonresponders (forced expiratory volume in 1 second
[FEV1] percent predicted, 89.36 4% vs. 89.26 13.7%; FEV1/FVC
forced vital capacity, 77.36 6.0% vs. 76.86 6.4%). Nonresponders
(502 of 1,073; 47%) had a gradual rise in mMRC scores starting
11 years after WTC exposure (Figure 2A), culminating in worse
dyspnea score at the end of longitudinal follow-up (1.55; 95%
confidence interval [CI], 1.40–1.70; vs. 0.79; 95% CI, 0.64–0.94,
respectively). When we assessed dyspnea trajectory relative to
treatment initiation (Figure 2B), we observed that responders had a
sharp increase in mMRC scores before treatment and a subsequent
decrease. Nonresponders, however, had a gradual rise in mMRC
scores before treatment initiation, which continued to increase
during treatment.
In an adjusted multivariable model, increased time between
9/11 and treatment initiation was a strong predictor of nonresponse
to therapy (Table 1). A higher pretreatment mMRC, however, was
significantly associated with a favorable response to treatment.
Discussion
This study produced longitudinal, patient-reported data on
dyspnea from 1,073 previously healthy WTC-exposed firefighters
who received more than 2 years of ICS/LABA treatment. The risk
factors for treatment were similar to risk factors for obstructive
airway disease in this cohort (7–10). We observed heterogeneity in
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Figure 2. Longitudinal modified Medical Research Council (mMRC) dyspnea
scale scores and 95% confidence intervals in linear mixed effects models,
stratified by responder type. mMRC scores were estimated using linear
mixed effects models with random intercepts, with categorized year, age,
body mass index, and race as fixed effects. The trajectory of the
responder group is shown as a solid blue line, and the trajectory in
the nonresponders is shown as a broken red line. (A) Trajectories of
mMRC scores relative to September 11, 2001 (9/11). Nonresponders
had a gradual rise in mMRC scores starting 11 years after WTC expo-
sure, culminating in worse dyspnea score at the end of longitudinal follow-
up. (B) Trajectories of mMRC scores relative to treatment initiation.
Responders had a sharp increase in mMRC scores before treatment,
followed by a subsequent decrease. Nonresponders, however, had a
gradual rise in mMRC scores before treatment initiation, which continued
to increase after inhaled corticosteroid/long-acting b-agonist (ICS/LABA)
initiation.
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dyspnea response, with only 53% of treated individuals responding
to treatment. We found that responders had rapidly increasing
dyspnea, as defined bymMRC score, in the 3 years before treatment
initiation. Notably, in responders, dyspnea improved for 5 years
after treatment initiation, returning to a level similar to baseline.
Nonresponders had gradually increasing dyspnea in the 3 years
before treatment, which continued to increase during the first 5
years after treatment initiation. This finding suggests that clinical
trials with patient-reported outcomes may benefit from longer
follow-up than that used in most randomized clinical trials.
Our study revealed pronounced differences in the trajectory of
dyspnea in responders and nonresponders to ICS/LABA treatment.
Responders presented earlier after WTC exposure, and higher
pretreatment mMRC score predicted favorable treatment response,
whereas nonresponders had a longer time between WTC exposure
and symptom onset or treatment initiation. This difference in onset
of symptoms suggests that nonresponders might have a different
endotype of obstructive airway disease that is less responsive to ICS/
LABA therapy. The lack of response to ICS/LABA therapy in those
with later-onset dyspnea might be indicative of a less inflammatory
type of disease.
One limitation of this study may include generalizability to
other affected individuals, because this single-center study of a
massively dust-exposed cohort included only previously healthy
males. We also acknowledge that there may be unmeasured
confounding, which is possible in all observational studies. In
addition, although regression to the mean might also contribute to
the difference in symptom score trajectories between responders
and nonresponders, the greater symptom burden of nonresponders
at the end of follow-up suggests that regression to the mean is
unlikely to be the sole or even main explanation for the observed
effect.
Conclusions. This longitudinal study showed that almost half
of irritant-exposed patients had worsening dyspnea after
ICS/LABA initiation. Treatment benefited more symptomatic
individuals who initiated ICS/LABA treatment sooner after WTC
exposure.
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Vasopressor Dosing in Septic Shock Clinical Trials:
A Systematic Review and Ecologic Study
To the Editor:
Predictive and prognostic enrichment have been proposed as
strategies to improve clinical trials in sepsis (1). By selecting
patients more likely to respond to treatment, or by identifying
patients at higher risk for a given outcome (up to 50% risk), smaller
sample sizes are needed to detect differences between treatment
groups.
Patient factors associated with increased mortality in septic
shock trials have been assessed, including presence or absence of
vasopressors and Sequential Organ Failure Assessment score (2).
However, even after accounting for these factors, there remains
wide variation in mortality rates between septic shock trials. We
hypothesized that higher vasopressor dose rate on enrollment,
which has been previously used for prognostic enrichment in
trials (3, 4), may serve as a marker of severity of shock, and may
therefore be helpful as a simple prognostic enrichment tool in
future trials.
Methods
We adapted a previous search strategy (2), extending the search
period from January 2006 to September 2019 and including only
trials that used norepinephrine as an inclusion criterion, and that
reported 28/30-day, intensive care unit, in-hospital, or 90-day
mortality. All stages of review were performed independently by
two reviewers.
The primary exposure was the minimum vasopressor dose rate
required for study inclusion. The secondary exposure was the
average (mean/median) vasopressor rate given to patients on
study inclusion. Studies that did not report the secondary
exposure were excluded from the secondary analysis. All
nonnorepinephrine vasopressor doses were converted into
norepinephrine equivalents using either equivalence calculations
provided in the study, or the table from Ranieri and colleagues
(5). Doses of vasopressors, reported as micrograms per
minute, were divided by 70 kg to calculate the approximate dose
(mg/kg/min) for comparison. Our primary outcome was 28/30-
day control-group mortality. When not present, 28/30-day
mortality was estimated using previously published regression
equations (2).
As sensitivity analyses, we excluded studies that did not report
28/30-day control-groupmortality, repeated our secondary analysis
using alternative equivalence conversions (6), and assessed
sensitivity of our findings to exclusion of noncatecholamine
vasopressors.
We used random-effects meta-analysis to calculate overall
control group mortality and rate of multiple vasopressors, and
random-effects metaregression to assess the association between
vasopressor doses and mortality. Mortality rates were logit-
transformed before meta-analysis and metaregression.
Results
A total of 30 septic shock trials met inclusion criteria (Table 1) (2,
7–10). A total of 10 trials specified a minimum fluid administration
volume before enrollment, ranging from 500 ml to approximately
2,000 ml (30 ml/kg); 6 trials required central venous pressure
>8 mm Hg or pulmonary artery occlusion pressure >12 mm Hg
before enrollment; 9 studies with a total of 353 patients did not
report 28/30-day mortality, but reported intensive care unit,
in-hospital, or 90-day mortality, from which 28/30-day mortality
was estimated (2).
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